A multicenter study of gemcitabine-containing regimen in relapsed or refractory Hodgkin's lymphoma patients

Anti-Cancer Drugs

Volumn 19, Issue 3, 2008, Pages 309-315

  Validire, Patricia ^a   Fermé, Christophe ^d   Brice, Pauline ^b   Diviné, Marine ^e   Gabarre, Jean ^c   Bouabdallah, Krimo ^f   Fitoussi, Olivier ^g   Chaoui, Driss ^h   Pacquement, Hélène ^a   Soussain, Carole ⁱ   Carde, Patrice ^d   Salhi, Rafika ^a   Zanni, Manuela ^a   Decaudin, Didier ^a  

^a INSTITUT CURIE   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f HAUT LÉVÊQUE HOSPITAL   (France)

^g Polyclinique Bordeaux Nord Aquitaine ^*  (France)

^h CENTRE HOSPITALIER VICTOR DUPOUY   (France)

ⁱ CENTRE RENÉ HUGUENIN   (France)

Author keywords

Gemcitabine; Hodgkin's lymphoma

Indexed keywords

CORTICOSTEROID; DOXORUBICIN; GEMCITABINE; HEMOGLOBIN; NAVELBINE; OXALIPLATIN; RITUXIMAB; VINBLASTINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BRONCHITIS; CANDIDIASIS; CATHETER INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HODGKIN DISEASE; HUMAN; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; OVERALL SURVIVAL; PANCYTOPENIA; PERITONITIS; PRIORITY JOURNAL; PROGNOSIS; RASH; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SEPTICEMIA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; URINARY TRACT INFECTION; CANCER STAGING; DOSE RESPONSE; DRUG RESISTANCE; METABOLISM; MIDDLE AGED; RECURRENT DISEASE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMOGLOBINS; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 45549106244     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3282f46aec     Document Type: Article

References (35)

1. Rosenberg S, Kaplan H. The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease. Int J Radiat Oncol Biol Phys 1985; 11:5-22.
2. Urba W, Long D. Hodgkin's disease. N Engl J Med 1992; 326: 678-687.
3. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327:1478-1484.
4. Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreunschuh M, Latha B, et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's disease lymphoma: interim report from a trial of the German Hodgkin's lymphoma Study Group. J Clin Oncol 1998; 16:3810-3821.
5. Longo D, Duffey P, Young R, Hubbard SM, Ihde DC, Glatstein E, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992; 10:210-218.
6. Linch D, Winfield D, Goldstone A, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341:1051.
7. Bolwell BJ, Kalaycio M, Goormastic M, Dannley R, Andresen SW, Lichtin A, et al. Progressive disease after ABMT for Hodgkin's disease. Bone Marrow Transplant 1997; 20:761-765.
8. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haematopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359:2065-2070.
9. Schnell R, Dietlein M, Staak JO, Borchmann P, Schomaecker K, Fischer T, et al. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol 2005; 23:4669-4678.
10. Vriesendorp HM, Morton JD, Quadri SM. Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease. Cancer Res 1995; 55:5888S-5892S.
11. 90yttrium-labelled antiferritin antibody. Anticancer Drugs 2006; 17:685-695.
12. Hu XF, Xing PX. MDX-060. Medarex. Curr Opin Invest Drugs 2005; 6:1266-1271.
13. Schnell R, Borchmann P. SGN-30 (Seattle genetics). Curr Opin Mol Ther 2006; 8:164-172.
14. Little R, Wittes RE, Longo DL, Wilson WH. Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant. J Clin Oncol 1998; 16:584-588.
15. Devizzi L, Santoro A, Bonfante V, Viviani S, Balzarini L, Valagussa P, et al. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease. Ann Oncol 1994; 5:817-820.
16. Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 1996; 23:3-15.
17. Van Zandwijk N, Smit EF, Kramer GW, Schramel F, Gans S, Festen J, et al. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative group (EORTC 08955). J Clin Oncol 2000; 18:2658-2664.
18. Von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer. J Clin Oncol 2000; 18:3068-3077.
19. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002; 94:902-910.
20. Santoro A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani S, et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 2000; 18:2615-2619.
21. Zinzani PL, Bendandi M, Stefoni V, Albertini P, Gherlinzoni F, Tani M, et al. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica 2000; 85:926-929.
22. Venkatesh H, Di Bella N, Flynn TP, Vellek MJ, Boehm KA, Asmar L. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma. Clin Lymphoma 2004; 5:110-115.
23. Aurer I, Radman I, Nemet D, Zupancić-Salek S, Bogdanić V, Mrsić M, et al. Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease. Onkologie 2005; 28:567-571.
24. Kuruvilla J, Nagy T, Pintilie M, Tsang R, Keating A, Crump M. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 2005; 106:353-360.
25. Ng M, Waters J, Cunningham D, Chau I, Horwich A, Hill M, et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer 2005; 92:1352-1357.
26. Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007; 18:1071-1079.
27. Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 2007; 92: 35-41.
28. Harris NL, Jaffe ES, Diébold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3849-3855.
29. Oken MM, Creech RH, Tormay DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-655.
30. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7:1630-1636.
31. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998; 339:1506-1514.
32. Lee CK, Bloomfield CD, Goldman AI, Levitt SH. Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy. Cancer 1980; 46:2403-2409.
33. Cheson BD, Horning JS, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1992; 17:1244-1253.
34. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
35. Bredenfeld H, Franklin J, Nogova L, Josting A, Fries S, Mailänder V, et al. Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2004; 22:2424-2429.